FDA Denies Remaining Sunscreen TEAs, Offers Primer On Why They Fail

In proposed orders to be published Feb. 25, FDA rejects L'Oreal USA’s time and extent application for ecamsule and Merck & Co.’s TEA for enzacamene. Division of Nonprescription Clinical Evaluation Director Theresa Michele acknowledges the decisions “may be disappointing to some.”